Full history for every metric is available with a Kvantra account
Cyclo Therapeutics, Inc. (CYTH)
Key financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 1 | 1 | 1 | 2 | 1 | 1 | 1 |
| Operating profit | $m | -20 | -25 | |||||
| Net profit | $m | -4 | -8 | -9 | -14 | -15 | -20 | -25 |
| EPS reported | $ | -1.23 | -0.90 | |||||
| Operating cashflow per share | $ | -0.99 | -0.99 | |||||
| Capex per share | $ | 0.00 | 0.00 | |||||
| FCF per share | $ | -0.99 | -0.99 | |||||
| Free cash flow | $m | -16 | -26 | |||||
| Net debt | $m | -9 | 11 | |||||
| Book value equity | $m | 5 | -13 | |||||
| Book value per share | $ | 0.29 | -0.47 | |||||
| Number of shares | m | 16.33 | 28.73 | |||||
| DPS (TTM paid) | $ | 0.00 | 0.00 |
Financial summary
Financials in USD| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 5.46 | -1.75 | |||||
| P/S LTM | x | 24.12 | 27.09 | |||||
| P/FCF LTM | x | -1.60 | -0.89 | |||||
| EV/EBITDA LTM | x | -0.89 | -1.41 | |||||
| EV/Sales LTM | x | 16.49 | 40.01 | |||||
| Earnings Yield LTM | % | -77.25% | -170.45% | |||||
| FCF Yield | % | -62.35% | -111.78% | |||||
| Quality | ||||||||
| ROE | % | -421.64% | -730.48% | |||||
| ROIC | % | -346.28% | -346.28% | |||||
| Operating margin | % | -1862.7% | -1862.7% | |||||
| Gross margin | % | 90.85% | 90.85% | |||||
| FCF/Sales | % | -1503.8% | -1503.8% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | -21.76% | -8.52% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 0.00% | |||||
| Dividend Growth | % | 0.00% | 0.00% | |||||
| Payout Ratio | % | 0.00% | 0.00% | |||||
| FCF/Debt | x | -15.67 | -2.16 | |||||
| Net Debt/EBITDA | x | 0.41 | 0.41 | |||||
| EBIT/Net interest | x | 0.00 | 0.00 | |||||
| Net debt/market cap | % | -35.61% | 47.69% | |||||
| Net debt/Equity | x | -1.94 | -0.83 | |||||
| Gross debt/equity | x | 0.22 | -0.91 | |||||
Company overview
Cyclo Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise focused on developing treatments derived from cyclodextrins for various health conditions. Its flagship therapeutic candidate, Trappsol Cyclo, holds orphan drug status and is presently in Phase III clinical trials targeting Niemann-Pick Type C disease. The company is also investigating Trappsol Cyclo's efficacy in addressing Alzheimer's disease. Beyond its drug development pipeline, the firm engages in the sale of cyclodextrins and related commodities to sectors such as pharmaceuticals and nutrition, primarily for their application in diagnostics and specialized drug formulations. Originally established in 1990 as CTD Holdings, Inc., the company adopted its current name, Cyclo Therapeutics, Inc., in September 2019 and maintains its headquarters in Gainesville, Florida.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Cyclo Therapeutics, Inc. (CYTH)
Cyclo Therapeutics, Inc. operates as a clinical-stage biotechnology enterprise focused on developing treatments derived from cyclodextrins for various health conditions. Its flagship therapeutic candidate, Trappsol Cyclo, holds orphan drug status and is presently in Phase III clinical trials targeting Niemann-Pick Type C disease. The company is also investigating Trappsol Cyclo's efficacy in addressing Alzheimer's disease. Beyond its drug development pipeline, the firm engages in the sale of cyclodextrins and related commodities to sectors such as pharmaceuticals and nutrition, primarily for their application in diagnostics and specialized drug formulations. Originally established in 1990 as CTD Holdings, Inc., the company adopted its current name, Cyclo Therapeutics, Inc., in September 2019 and maintains its headquarters in Gainesville, Florida.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free